These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 27843451)

  • 1. Effects of Inositol(s) in Women with PCOS: A Systematic Review of Randomized Controlled Trials.
    Unfer V; Nestler JE; Kamenov ZA; Prapas N; Facchinetti F
    Int J Endocrinol; 2016; 2016():1849162. PubMed ID: 27843451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome.
    Unfer V; Porcaro G
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):623-31. PubMed ID: 24898153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials.
    Unfer V; Carlomagno G; Dante G; Facchinetti F
    Gynecol Endocrinol; 2012 Jul; 28(7):509-15. PubMed ID: 22296306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review.
    Gateva A; Unfer V; Kamenov Z
    Gynecol Endocrinol; 2018 Jul; 34(7):545-550. PubMed ID: 29309199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Myo-inositol in the treatment of polycystic ovary syndrome].
    Křepelka P
    Ceska Gynekol; 2014 Jun; 79(3):242-6. PubMed ID: 25054962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CONCERN: Does ovary need D-chiro-inositol?
    Isabella R; Raffone E
    J Ovarian Res; 2012 May; 5(1):14. PubMed ID: 22587479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polycystic ovary syndrome (PCOS) and hyperandrogenism: the role of a new natural association.
    Morgante G; Cappelli V; Di Sabatino A; Massaro MG; De Leo V
    Minerva Ginecol; 2015 Oct; 67(5):457-63. PubMed ID: 26491824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of combination therapy of inositols, antioxidants and vitamins in obese and non-obese women with polycystic ovary syndrome: an observational study.
    Advani K; Batra M; Tajpuriya S; Gupta R; Saraswat A; Nagar HD; Makwana L; Kshirsagar S; Kaul P; Ghosh AK; Pradhan S; Mehta A; Jaiswal A; Nakhate KT; Kamdi S
    J Obstet Gynaecol; 2020 Jan; 40(1):96-101. PubMed ID: 31339394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between effects of myo-inositol and D-chiro-inositol on ovarian function and metabolic factors in women with PCOS.
    Pizzo A; Laganà AS; Barbaro L
    Gynecol Endocrinol; 2014 Mar; 30(3):205-8. PubMed ID: 24351072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inositol Treatment and ART Outcomes in Women with PCOS.
    Garg D; Tal R
    Int J Endocrinol; 2016; 2016():1979654. PubMed ID: 27795706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Metabolic Consequences of Insulin Resistance in Polycystic Ovary Syndrome by D-chiro-inositol and Emerging Nutraceuticals: A Focused Review.
    Davinelli S; Nicolosi D; Di Cesare C; Scapagnini G; Di Marco R
    J Clin Med; 2020 Apr; 9(4):. PubMed ID: 32252239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myo-inositol vs. D-chiro inositol in PCOS treatment.
    Formuso C; Stracquadanio M; Ciotta L
    Minerva Ginecol; 2015 Aug; 67(4):321-5. PubMed ID: 25670222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining treatment with myo-inositol and D-chiro-inositol (40:1) is effective in restoring ovary function and metabolic balance in PCOS patients.
    Monastra G; Unfer V; Harrath AH; Bizzarri M
    Gynecol Endocrinol; 2017 Jan; 33(1):1-9. PubMed ID: 27898267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients.
    Minozzi M; Nordio M; Pajalich R
    Eur Rev Med Pharmacol Sci; 2013 Feb; 17(4):537-40. PubMed ID: 23467955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.
    Nordio M; Proietti E
    Eur Rev Med Pharmacol Sci; 2012 May; 16(5):575-81. PubMed ID: 22774396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The inositols and polycystic ovary syndrome.
    Kalra B; Kalra S; Sharma JB
    Indian J Endocrinol Metab; 2016; 20(5):720-724. PubMed ID: 27730087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inositol supplementation in women with polycystic ovary syndrome undergoing intracytoplasmic sperm injection: a systematic review and meta-analysis of randomized controlled trials.
    Mendoza N; Pérez L; Simoncini T; Genazzani A
    Reprod Biomed Online; 2017 Nov; 35(5):529-535. PubMed ID: 28756130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. D-Chiro-inositol and PCOS: between myth and reality. The never-ending story.
    Cianci A; Vitale SG
    Int J Food Sci Nutr; 2022 Aug; 73(5):565-570. PubMed ID: 35057707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycystic Ovary Syndrome: Insights into the Therapeutic Approach with Inositols.
    Sortino MA; Salomone S; Carruba MO; Drago F
    Front Pharmacol; 2017; 8():341. PubMed ID: 28642705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.